Logo 1 Logo 2

Clinical Trial Details

Trial ID: L2720
Source ID: NCT00417729
Associated Drug: Acarbose
Title: Effects of Acarbose Versus Glibenclamide on MAGE and Oxidative Stress in Patients With Type 2 DM
Acronym:
Status: COMPLETED
Study Results: NO
Results:
Conditions: Diabetes Mellitus
Interventions: DRUG: Acarbose
Outcome Measures: Primary: Mean Amplitude Glycemic Excursion, A Medtronic MiniMed Continuous Glucose Monitoring System (Northridge, CA) was used for continuous glucose measurements on an ambulatory basis for 72 consecutive hours and MAGE calculated from the dataset., before randomisation and end of study|Oxidative stress, Spot urine was collected for measurement of 8-iso PGF2 alpha excretion rate., before randomisation and end of study | Secondary: HbA1c, Glycated hemoglobin for evaluation of efficacy of glycemic control., before randomisation and end of study|fasting glucose, after an overnight fasting, before randomisation and end of study|Insulin response, Evaluation by meal tolerance test. Patients were asked to consume 1.5 cans of Ensure Liquid (266 kcal/can, caloric contribution: 64% carbohydrate, 14% fat, and 22% protein) after a 10-h overnight fasting. Blood samples were drawn at 0, 10, 20, 30, 60, 90, 120, and 180 minute relative to the meal ingestion for the measurements of glucose and insulin., before randomisation and end of study|Fasting lipids, after an overnight fasting, before randomisation and end of study|hsCRP, high-sensitivity C-reactive protein, before randomisation and end of study|oxLDL, oxidized low-density lipoprotein, before randomisation and end of study|Adiponectin, Total and high-molecular weight adiponectin, before randomisation and end of study
Sponsor/Collaborators: Sponsor: Taichung Veterans General Hospital | Collaborators: Taipei Veterans General Hospital, Taiwan|Changhua Christian Hospital
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE4
Enrollment: 51
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
Start Date: 2007-01
Completion Date: 2009-01
Results First Posted:
Last Update Posted: 2010-05-12
Locations: Taichung Veterans General Hospital, Taichung, Taiwan
URL: https://clinicaltrials.gov/show/NCT00417729